MAP2K7 and Miyoshi myopathy: In this population of patients, in individuals with the KIT mutation, imatinib was reported to result in significant clinical benefits, while for MM patients whose tumors harbor BRAF mutations, treatment with a combination of BRAF and MEK inhibitors was shown to be effective [8,24].